Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion
The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023
Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis
Age ≥18 years at the time of inclusion
You may not be if
Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection
Patients received trastuzumab deruxtecan
The participation in any interventional trial within period since diagnosis until the end of study